Wegovy vs Zepbound: A Complete Comparison for Weight Loss — Which GLP-1 Medication Is Right for You?

When patients ask me about the Wegovy vs Zepbound comparison, here is the bottom line from over 20 years of bariatric practice and more than 4,000 weight-loss surgeries: both are highly effective GLP-1 medications that represent a genuine breakthrough in obesity treatment, but they are not identical. Zepbound (tirzepatide) tends to produce greater average weight loss in clinical trials — roughly 20–25% of body weight at the highest dose — while Wegovy (semaglutide) delivers approximately 15–17%. That said, which GLP-1 medication is better for you depends on much more than headline numbers. It depends on your medical history, how your body responds, insurance coverage, and your long-term plan for keeping the weight off.

Below, I’ll walk you through everything you need to know — the science behind each drug, real-world weight-loss expectations, side effects, cost considerations, and how these medications fit into a comprehensive weight-management strategy that may also include bariatric surgery.

How Do Wegovy and Zepbound Actually Work?

Before we compare results, it helps to understand the mechanism. Both drugs are injectable medications given once a week, but they target different hormonal pathways.

Wegovy (Semaglutide)

Wegovy is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after eating. It signals your brain to feel full, slows gastric emptying so food stays in your stomach longer, and helps regulate blood sugar. Semaglutide mimics this hormone at much higher levels than your body produces naturally, creating a powerful appetite-suppressing effect.

Wegovy was approved by the FDA for chronic weight management in June 2021. It is manufactured by Novo Nordisk and is essentially the same molecule used in Ozempic (the diabetes formulation), but dosed specifically for obesity.

Zepbound (Tirzepatide)

Zepbound is a dual GIP/GLP-1 receptor agonist. In addition to activating GLP-1 receptors like Wegovy does, tirzepatide also activates GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is another gut hormone involved in metabolism, insulin secretion, and — researchers now believe — fat storage regulation. By hitting two receptors instead of one, tirzepatide appears to amplify the metabolic and appetite-suppressing effects beyond what GLP-1 alone can achieve.

Zepbound was approved by the FDA for chronic weight management in November 2023. It is manufactured by Eli Lilly and uses the same molecule as Mounjaro (the diabetes formulation).

How Much Weight Can You Lose on Wegovy vs Zepbound?

This is the question everyone wants answered, so let’s look at the clinical trial data.

Wegovy Clinical Trials (STEP Program)

The landmark STEP 1 trial, published in the New England Journal of Medicine in 2021, enrolled adults with obesity or overweight with at least one weight-related condition. At 68 weeks on the maximum 2.4 mg dose:

• Average weight loss: 14.9% of body weight (vs. 2.4% for placebo)
• About one-third of participants lost 20% or more of their body weight
• Significant improvements in waist circumference, blood pressure, and lipid profiles

For a person weighing 250 pounds, that translates to roughly 37 pounds on average — a meaningful change, though results varied widely from person to person.

Zepbound Clinical Trials (SURMOUNT Program)

The SURMOUNT-1 trial, also published in the New England Journal of Medicine in 2022, studied tirzepatide in a similar population. At 72 weeks on the maximum 15 mg dose:

• Average weight loss: 22.5% of body weight (vs. 2.4% for placebo)
• More than one-third of participants lost 25% or more of their body weight
• Over half of participants lost 20% or more — a threshold that approaches surgical weight loss

For that same 250-pound person, this translates to roughly 56 pounds — a striking result for a medication alone.

The Head-to-Head Data: Semaglutide vs Tirzepatide Weight Loss

The SURMOUNT-5 trial, presented in 2024, provided the first direct head-to-head comparison of semaglutide vs tirzepatide for weight loss. The results confirmed what the separate trials suggested:

• Patients on tirzepatide 15 mg lost approximately 20.2% of their body weight
• Patients on semaglutide 2.4 mg lost approximately 13.7% of their body weight
• The difference — roughly 6.5 percentage points — was statistically significant

So when patients ask me directly, “Which GLP-1 medication is better for weight loss?” the data favors Zepbound on average. But I always add a critical caveat: averages don’t tell individual stories. I have patients who lost 20% on Wegovy and patients who lost only 10% on Zepbound. Biology is personal.

What About the Side Effects?

Both Wegovy and Zepbound share a similar side-effect profile, which makes sense given that they both activate GLP-1 receptors. The most common complaints are gastrointestinal.

Common Side Effects of Both Medications

• Nausea — the most frequently reported side effect, especially during dose escalation
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain
• Injection-site reactions (mild redness, itching)

In my clinical experience, nausea is worst during the first few weeks at each new dose level. Both medications use a gradual dose-escalation schedule specifically to minimize this — you start at a low dose and increase every four weeks until you reach the target.

Are Zepbound Side Effects Worse Than Wegovy?

Because Zepbound acts on two receptors, some patients do experience more intense GI symptoms, particularly at higher doses. The SURMOUNT-5 head-to-head trial showed that discontinuation rates due to side effects were modestly higher with tirzepatide than with semaglutide. However, the differences were not dramatic, and most patients in both groups were able to tolerate the medications long-term.

I tell my patients that the side effects are generally manageable with a few strategies:

• Eat smaller, more frequent meals
• Avoid high-fat and greasy foods, especially early on
• Stay well-hydrated
• Don’t rush the dose escalation — if you’re miserable, stay at the current dose a bit longer

Serious but Rare Risks

Both medications carry warnings for:

• Pancreatitis — rare but serious; seek immediate care for severe abdominal pain
• Gallbladder disease — rapid weight loss from any cause increases gallstone risk
• Thyroid C-cell tumors — observed in animal studies; both carry a boxed warning, and neither should be used in patients with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome
• Gastroparesis-like symptoms — severe delayed gastric emptying in a small subset of patients

How Much Do Wegovy and Zepbound Cost?

Let’s talk about the elephant in the room. Without insurance, both medications carry list prices that are staggering for most families.

Note: Prices fluctuate, and Eli Lilly has introduced lower-priced vials of tirzepatide through its LillyDirect program. Always check current pricing and your specific insurance formulary.

Insurance coverage for GLP-1 medications is evolving rapidly. Some commercial plans cover one but not the other, and prior authorization requirements vary. If cost is a significant barrier — and for many patients it is — this factor alone can determine which medication makes more practical sense.

Wegovy Has a Cardiovascular Advantage — For Now

One area where Wegovy currently has an edge has nothing to do with the number on the scale. The SELECT trial, published in the New England Journal of Medicine in 2023, demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) by 20% in adults with obesity and established cardiovascular disease — independent of weight loss.

This is a landmark finding. It means that for patients with heart disease or a high cardiovascular risk profile, Wegovy offers a proven benefit beyond weight management. The FDA updated Wegovy’s label in March 2024 to include this cardiovascular indication.

Zepbound does not yet have equivalent cardiovascular outcome data, though Eli Lilly’s SURPASS-CVOT trial is underway. Given tirzepatide’s metabolic profile, many experts anticipate positive results, but until the data are in, Wegovy holds this distinction.

For my patients with a history of heart attack, stroke, or significant atherosclerotic disease, this cardiovascular evidence often tips the Wegovy vs Zepbound decision toward Wegovy — even if the raw weight-loss numbers are slightly lower.

How Do Wegovy and Zepbound Compare to Bariatric Surgery?

As a bariatric surgeon who has performed over 4,000 procedures and who also prescribes these medications regularly, I think this question deserves honest context.

Bariatric surgery — procedures like gastric sleeve and gastric bypass — remains the most effective and durable treatment for severe obesity. Patients typically lose 25–35% of their body weight after surgery and, crucially, tend to maintain a substantial portion of that loss for 10 years and beyond.

Zepbound’s results at the highest dose approach surgical-level weight loss in the short term (22.5% in SURMOUNT-1), which is genuinely impressive. But there is a critical difference: durability.

The SURMOUNT-4 trial showed that when patients stopped tirzepatide after 36 weeks, they regained approximately 14% of their body weight over the following year. The STEP 1 extension trial showed a similar pattern with semaglutide — patients regained roughly two-thirds of lost weight within a year of stopping.

This doesn’t mean medications are a failure. It means that, for most people, these drugs need to be taken long-term to maintain results. That has profound implications for cost, access, and planning.

In my practice, I see GLP-1 medications and surgery as complementary tools, not competing ones. Some patients do beautifully on medication alone. Others use medication as a bridge to surgery, or use medication after surgery to overcome a plateau. The best approach is individualized — which is exactly why working with an experienced team matters.

Which One Should You Choose? A Practical Decision Framework

After walking hundreds of patients through this exact semaglutide vs tirzepatide decision, here’s the framework I use:

Zepbound May Be the Better Choice If:

• Maximum weight loss is your primary goal and you don’t have significant cardiovascular disease
• Your insurance covers it or you can manage the out-of-pocket cost
• You tolerate GI side effects reasonably well
• You have significant insulin resistance or type 2 diabetes (tirzepatide’s dual mechanism offers robust glucose control)

Wegovy May Be the Better Choice If:

• You have established cardiovascular disease or high cardiovascular risk — the SELECT trial data is compelling
• Your insurance covers Wegovy but not Zepbound (or vice versa — availability matters)
• You’ve tried semaglutide before (in Ozempic or Rybelsus form) and responded well
• You prefer the option with a longer track record on the market

Either Medication May Not Be the Best Fit If:

• You have a history of medullary thyroid carcinoma or MEN 2 syndrome
• You have a history of pancreatitis
• You’re planning to become pregnant in the near term (both should be discontinued well before conception)
• You have severe gastroparesis
• The cost is unsustainable and you have no realistic path to long-term coverage

What Happens When You Stop Taking These Medications?

I mentioned this briefly above, but it warrants its own section because it’s the number-one concern I hear from patients who are weighing Wegovy or Zepbound.

The honest answer: most patients regain weight after stopping. The STEP 1 extension and SURMOUNT-4 data make this clear. Obesity is a chronic, relapsing condition driven by biology — hormones, genetics, brain chemistry — not willpower. When you remove the medication that was modifying those biological drivers, the drivers reassert themselves.

This is not a reason to avoid these medications. It’s a reason to plan ahead. In my practice, we discuss the long-term strategy before starting treatment:

• Can you realistically stay on medication indefinitely?
• Would bariatric surgery offer a more durable solution?
• What lifestyle foundations — nutrition, exercise, sleep, stress management — can you build while the medication is working, so that you maintain as much benefit as possible?

These are the conversations that separate thoughtful obesity medicine from simply writing prescriptions.

The Bottom Line: Wegovy vs Zepbound in 2024 and Beyond

Both Wegovy and Zepbound are remarkable medications that have changed the landscape of obesity treatment. If I had to distill the comparison:

• For raw weight-loss potency, Zepbound (tirzepatide) has the edge based on current clinical trial data.
• For proven cardiovascular protection, Wegovy (semaglutide) stands alone — for now.
• For tolerability, both are similar, with a slight edge to Wegovy in terms of lower discontinuation rates.
• For cost, the landscape shifts constantly; check your coverage and explore savings programs.
• For durability, neither medication is a permanent fix when used alone. Long-term planning is essential.

As a bariatric surgeon who has spent over two decades helping patients achieve lasting weight loss, I believe the most important decision isn’t Wegovy or Zepbound — it’s committing to a comprehensive, medically supervised plan that uses the right tools at the right time for your unique situation.

If you’re considering GLP-1 medications or wondering whether medication, bariatric surgery, or a combination approach is the right path for you, the next step is a thorough evaluation with a physician who understands the full spectrum of obesity treatment options. That evaluation should include your medical history, metabolic profile, insurance situation, and — most importantly — your long-term goals.